SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

1

SGLT2 inhibitors are linked to a 45% lower risk of late-onset epilepsy in patients aged 60 and older compared to DPP-4 inhibitors.
2

Patients using SGLT2 inhibitors showed a 62% lower risk of status epilepticus and a 37% lower risk of starting antiseizure medications.
3

Cumulative incidence curves indicated significant differences in epilepsy risk between SGLT2 and DPP-4 inhibitor groups throughout the follow-up.
4

Subgroup analyses revealed lower risks of late-onset epilepsy in patients with prior stroke and dementia when using SGLT2 inhibitors.
5

The study's observational design limits causality conclusions, and several limitations were noted, including reliance on coded diagnoses.

1